Submissions from 2025
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., Writing Committee for the HEALEY ALS Platform Trial, James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik, Melanie Quintana, Benjamin R Saville, Michelle A Detry, Matteo Vestrucci, Joseph Marion, Anna McGlothlin, Elijah W Stommel, Marianne Chase, Lindsay Pothier, Brittney A Harkey, Hong Yu, Alex Sherman, Jeremy Shefner, Meghan Hall, Gale Kittle, Suma Babu, Jinsy Andrews, Derek D'Agostino, Eric Tustison, Erica Scirocco, Elisa Giacomelli, Gustavo Alameda, Eduardo Locatelli, Doreen Ho, Adam Quick, Senda Ajroud-Driss, Jonathan Katz, Daragh Heitzman, Stanley H Appel, Sheetal Shroff, Kevin J Felice, Zachary Simmons, Timothy Miller, Nicholas Olney, Michael D Weiss, Stephen A Goutman, Joseph Americo Fernandes, Omar Jawdat, Margaret Ayo Owegi, Laura Foster, Tuan Vu, Hristelina Ilieva, Daniel S Newman, Ximena Arcila-Londono, Carlayne Jackson, Shafeeq Ladha, Terry Heiman-Patterson, James Caress, Andrea Swenson, Amanda Peltier, Richard Lewis, Dominic Fee, Matthew Elliott, Richard Bedlack, Edward J Kasarskis, Lauren Elman, Jeffrey Rosenfeld, David Walk, Courtney E McIlduff, Paul Twydell, Eufrosina Young, Kristin Johnson, Kourosh Rezania, Namita A Goyal, Jeffrey A Cohen, Michael Benatar, Vovanti Jones, Jonathan Glass, Jaimin Shah, Said R Beydoun, James P Wymer, Lindsay Zilliox, Shakti Nayar, Gary L Pattee, Jennifer Martinez-Thompson, Austin Rynders, Jacob Evan, Jeremy Evan, Alan Hartford, Marjan Sepassi, Karen S Ho, Robert Glanzman, Benjamin Greenberg, Michael T Hotchkin, Sabrina Paganoni, Merit E Cudkowicz, and HEALEY ALS Platform Trial Study Group
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., Writing Committee for the HEALEY ALS Platform Trial, Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik, Melanie Quintana, Benjamin R Saville, Michelle A Detry, Matteo Vestrucci, Joe Marion, Anna McGlothlin, Terry Heiman-Patterson, Marianne Chase, Lindsay Pothier, Brittney A Harkey, Hong Yu, Alexander V Sherman, Meghan Hall, Gale Kittle, James D Berry, Suma Babu, Jinsy Andrews, Derek D'Agostino, Eric Tustison, Erica Scirocco, Elisa Giacomelli, Gustavo Alameda, Eduardo Locatelli, Doreen Ho, Adam Quick, Senda Ajroud-Driss, Jonathan Katz, Daragh Heitzman, Stanley H Appel, Sheetal Shroff, Kevin Felice, Nicholas J Maragakis, Zachary Simmons, Timothy M Miller, Nicholas Olney, Michael D Weiss, Stephen A Goutman, Joseph Americo Fernandes, Omar Jawdat, Margaret Ayo Owegi, Laura A Foster, Tuan Vu, Hristelina Ilieva, Daniel S Newman, Ximena Arcila-Londono, Carlayne E Jackson, Shafeeq Ladha, James B Caress, Andrea Swenson, Amanda Peltier, Richard A Lewis, Dominic Fee, Matthew Elliott, Richard Bedlack, Edward J Kasarskis, Lauren Elman, Jeffrey Rosenfeld, David Walk, Courtney McIlduff, Paul Twydell, Eufrosina Young, Kristin Johnson, Kourosh Rezania, Namita A Goyal, Jeffrey A Cohen, Michael Benatar, Vovanti Jones, Jaimin Shah, Said R Beydoun, James P Wymer, Lindsay Zilliox, Shakti Nayar, Gary L Pattee, Jennifer Martinez-Thompson, Melanie L Leitner, Kelly Chen, Y Paul Goldberg, Yael Cohen, Michal Geva, Michael R Hayden, Sabrina Paganoni, Merit E Cudkowicz, and HEALEY ALS Platform Trial Study Group
Ceftriaxone-Induced Thrombocytopenia, Providence SVMC GME
Profiling a Multidisciplinary Team in Making a Change in Pharmaceutical Practice: Lessons Learned., Renee Rassilyer-Bomers, Diem Pham, Adam Corson, and Cara Gallegos
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity., Patricia J Rodriguez, Vincent Zhang, Samuel Gratzl, Duy Do, Brianna Goodwin Cartwright, Charlotte Baker, Ty J Gluckman, Nicholas Stucky, and Ezekiel J Emanuel
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study., Rachel E Sanborn, Caicun Zhou, Ke-Jing Tang, Byoung Chul Cho, Susanna Cheng, Sanjay Popat, Akira Ono, Shun Lu, Margarita Majem, Andres Aguilar, Maria Del Rosario Garcia Campelo, Hidetoshi Hayashi, Kang-Yun Lee, Se-Hoon Lee, Angelo Delmonte, Jorge Alatorre-Alexander, Gary Richardson, Victor Santos, Christophe Dooms, Joshua K Sabari, Catherine A Shu, Nicolas Girard, Aaron S Mansfield, Keunchil Park, Yichuan Xia, Archan Bhattacharya, Nasuh Buyukkaramikli, Nolen Perualila, Joris Diels, Sandip Acharya, Conor Chandler, Irina Proskorovsky, Lindsay Dearden, Honeylet Wortman-Vayn, Parthiv J Mahadevia, Roland E Knoblauch, Trishala Agrawal, Mahadi Baig, and Enriqueta Felip
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial., Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, William G Wierda, Chaitra S Ujjani, Toby A Eyre, Pier Luigi Zinzani, Alvaro J Alencar, Paolo Ghia, Nicole Lamanna, Marc S Hoffmann, Manish R Patel, Ian Flinn, James N Gerson, Shuo Ma, Catherine C Coombs, Chan Y Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A Barve, Jonathon B Cohen, Wojciech Jurczak, Talha Munir, Meghan C Thompson, Donald E Tsai, Katherine Bao, Nicholas A Cangemi, Jennifer F Kherani, Richard A Walgren, Hongmei Han, Amy S Ruppert, and Jennifer R Brown
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial., Stacey M Sklepinski, Yihong Deng, Kavya Sindu Swarna, Jeph Herrin, Eric C Polley, Joshua J Neumiller, Rodolfo J Galindo, Guillermo E Umpierrez, Joseph S Ross, Bijan J Borah, Bradley A Maron, Mindy M Mickelson, and Rozalina G McCoy
Pemigatinib for Previously Treated Metastatic or Unresectable Central Nervous System Tumors with FGFR Mutations or Rearrangements: FIGHT-207 Results., Iben Spanggaard, Marc Matrana, Caio Rocha Lima, Amit Mahipal, Maria Vieito, Alice Hervieu, Lipika Goyal, Jordi Rodón, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Michael Schaffer, and Santosh Kesari
Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America., Kateri J Spinelli and Allison H Oakes
DRUG AND SINGLE-CELL GENE EXPRESSION INTEGRATION IDENTIFIES SENSITIVE AND RESISTANT GLIOBLASTOMA CELL POPULATIONS., Robert K Suter, Anna M Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias, Grace Baker, Luz Ruiz, Winston Walters, Maria Cepero, Danielle Burgenske, Edward B Reilly, Anatol Oleksijew, Mark G Anderson, Sion Ll Williams, Michael E Ivan, Ricardo J Komotar, Macarena I De La Fuente, Gregory Stein, Alexander Wojcinski, Santosh Kesari, Jann N Sarkaria, Stephan C Schürer, and Nagi G Ayad
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study., Sara M Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L Puhalla, Alison Conlin, E Claire Dees, Muralidhar Beeram, Sonya C Chapman, Andrew Lithio, Lacey M Litchfield, and Matthew P Goetz
A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes., Katherine Tuttle, Lindsey M Kornowske, Cami R Jones, Christina L Reynolds, Radica Alicic, Kenn Daratha, Joshua J Neumiller, O Kenrik Duru, Susanne B Nicholas, Keith C Norris, and Meda E Pavkov
Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma., John L Villano, Catherine R Garcia, Rachael M Morgan, Shulin Zhang, Jill Kolesar, Farhan A Mirza, Timothy Samec, Joanne Xiu, Stephanie Rock, Santosh Kesari, Emil Lou, Sonikpreet Aulakh, Michael J Glantz, and Eric T Wong
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: The REAL-HLH study., Adi Zoref-Lorenz, Carl E Allen, Edward M Behrens, Shanmuganathan Chandrakasan, May Chien, Michelle L Hermiston, Ashley Hinson, Stefanos Intzes, Michael S Isakoff, Jennifer W Leiding, Abiola Oladapo, Arun Panigrahi, Sachit A Patel, Priti Pednekar, Anish Ray, Jennifer A Rothman, Blachy J Dávila Saldaña, Kelly Walkovich, Joanna L Weinstein, John D Yee, and Michael B Jordan
Submissions from 2024
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery., Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, A Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M Wallace, Henry G Kaplan, Lajos Pusztai, David Euhus, Rita Nanda, Anthony D Elias, Amy S Clark, Constantine Godellas, Judy C Boughey, Claudine Isaacs, Debu Tripathy, Janice Lu, Rachel L Yung, Rosa I Gallagher, Julia D Wulfkuhle, Lamorna Brown-Swigart, Gregor Krings, Yunn Yi Chen, David A Potter, Erica Stringer-Reasor, Sarah Blair, Smita M Asare, Amy Wilson, Gillian L Hirst, Ruby Singhrao, Meredith Buxton, Julia L Clennell, Ashish Sanil, Scott Berry, Adam L Asare, Jeffrey B Matthews, Angela M DeMichele, Nola M Hylton, Michelle Melisko, Jane Perlmutter, Hope S Rugo, W Fraser Symmans, Laura J Van't Veer, Douglas Yee, Donald A Berry, and Laura J Esserman
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain., Jessica R Allegretti, Krisztina B Gecse, Michael Chiorean, Marjorie Argollo, Xiang Guo, Nervin Lawendy, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Leonardo Salese, and Peter M Irving
Drug delivery in leptomeningeal disease: Navigating barriers and beyond., Numair Arshad, Nupur Biswas, Jaya Gill, Santosh Kesari, and Shashaanka Ashili
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014., Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous, Jesús G Berdeja, Jesse Shustik, Gary J Schiller, Siddhartha Ganguly, Kevin Song, Christopher S Seet, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Gustavo Fonseca, Hongjuan Liu, Christian Gentili, Pavit Singh, and David Siegel
Safety and real-world dosing of onabotulinumtoxinA for the treatment of adult spasticity: post hoc analysis of the Adult Spasticity International Registry study., Ganesh Bavikatte, Alberto Esquenazi, Michael A Dimyan, Khashayar Dashtipour, Wuwei Feng, Angeli Mayadev, Kristina Fanning, Tiziana Musacchio, Aleksej Zuzek, and Gerard E Francisco
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial., Michael Benatar, Thomas Hansen, Dror Rom, Marie A Geist, Thomas Blaettler, William Camu, Magdalena Kuzma-Kozakiewicz, Leonard H van den Berg, Raul Juntas Morales, Adriano Chio, Peter M Andersen, Pierre-Francois Pradat, Dale Lange, Philip Van Damme, Gabriele Mora, Mariusz Grudniak, Matthew Elliott, Susanne Petri, Nicholas T Olney, Shafeeq Ladha, Namita A Goyal, Thomas Meyer, Michael G Hanna, Colin Quinn, Angela Genge, Lorne Zinman, Duaa Jabari, Christen Shoesmith, Albert C Ludolph, Christoph Neuwirth, Sharon Nations, Jeremy M Shefner, Martin R Turner, Joanne Wuu, Richard Bennett, Hoang Dang, and Claus Sundgreen
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial., Stefan R Bornstein, Dick de Zeeuw, Hiddo J L Heerspink, Friedrich Schulze, Lisa Cronin, Arne Wenz, Katherine Tuttle, Samy Hadjadj, and Peter Rossing
An inconspicuous identification: Isolation and identification of a novel Pichia species presenting as fungemia following cardiac surgery., Allorie T Caldwell, Toni Gabaldón, Verónica Mixão, Nancy L Wengenack, Benjamin P Westley, and Ryan W Stevens
Safety and Efficacy of Empiric De-escalation of Antibiotics for Pneumonia in the Intensive Care Unit, Brandon Carron
Optimizing tacrolimus dosing in Hispanic renal transplant patients: insights from real-world data., Athanasios Chamzas, Eglis Tellez, Andrew SyBing, Jogarao V S Gobburu, and Mathangi Gopalakrishnan
Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO Phase 3 trial and open-label extension., Paul Clift, Felix Berger, Lars Sondergaard, Petra Antonova, Patrick Disney, Jeremy Nicolarsen, Jean-Benoît Thambo, Lidia Tomkiewicz Pajak, Jou-Kou Wang, Annette Schophuus Jensen, Michela Efficace, Michael Friberg, Diana Haberle, Verena Walter, and Yves d'Udekem
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study., Laura C Coates, Proton Rahman, Philip J Mease, May Shawi, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, Soumya D Chakravarty, Iain B McInnes, and Lai-Shan Tam
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment., Atul Deodhar, Alan J Kivitz, Marina Magrey, Jessica A Walsh, Philip J Mease, Maria Greenwald, Farid Kianifard, Chelsea Elam, Gopi M Bommidi, Adam Winseck, and Lianne S Gensler
Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial., Kurt de Vlam, Walter P Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J Bolce, and Philip G Conaghan
Naloxone: From Legislation to Distribution, Kailyn Elliot, Emily Stewart, and John Delfeld
Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses., Oliver FitzGerald, Dafna D Gladman, Philip Mease, Christopher Ritchlin, Josef S Smolen, Lu Gao, Yanhua Hu, Miroslawa Nowak, Subhashis Banerjee, and Ian Catlett
SYNCHRONIZE: Real-World Retrospective Safety Analysis of Patients Treated with OnabotulinumtoxinA for More than One Therapeutic Indication., Grace Forde, Benjamin M Brucker, Kimberly Becker Ifantides, Atul T Patel, A Mayadev, Theodore Brown, Ziyad Ayyoub, Kenneth Martinez, Ritu Singh, Mariana Nelson, Simona Battucci, Irina Yushmanova, Ahunna Ukah, and Christopher Rhyne
Left atrial appendage occlusion needs lifetime management not lifetime medications., Sameer Gafoor and Sidakpal S Panaich
Results from a benzodiazepine-minimizing protocol for inpatient management of alcohol withdrawal., Jennifer Gaston, Emily J Cox, Hsin-Fang Li, Caitlin Klamper, and John F Wurzel
Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis., Dafna D Gladman, Peter Nash, Philip J Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, and Karim R Masri
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial., Hiddo J L Heerspink, Rajiv Agarwal, George L Bakris, David Z I Cherney, Carolyn S P Lam, Brendon L Neuen, Pantelis A Sarafidis, Katherine Tuttle, Christoph Wanner, Meike D Brinker, Sara Dizayee, Peter Kolkhof, Patrick Schloemer, Paula Vesterinen, and Vlado Perkovic
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies., M Elaine Husni, Philip Mease, Joseph F Merola, William Tillett, Nadine Goldammer, Barbara Ink, Jason Coarse, Jérémy Lambert, Vanessa Taieb, and Dafna D Gladman
Accelerating adverse pregnancy outcomes research amidst rising medication use: parallel retrospective cohort analyses for signal prioritization., Yeon Mi Hwang, Samantha N Piekos, Alison G Paquette, Qi Wei, Nathan D Price, Leroy Hood, and Jennifer J Hadlock
Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period., Yeon Mi Hwang, Ryan T Roper, Samantha N Piekos, Daniel A Enquobahrie, Mary F Hebert, Alison G Paquette, Priyanka Baloni, Nathan D Price, Leroy Hood, and Jennifer J Hadlock
A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer., Tiffany Juarez, Jaya Mini Gill, Annie Heng, Jose Carrillo, Naveed Wagle, Natsuko Nomura, Minhdan Nguyen, Judy D Truong, Lucia Dobrawa, Walavan Sivakumar, Garni Barkhoudarian, Daniel F Kelly, and Santosh Kesari
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial., Arthur Kavanaugh, Laura C Coates, Philip Mease, Miroslawa Nowak, Lauren Hippeli, Thomas Lehman, Subhashis Banerjee, and Joseph F Merola
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., Santosh Kesari, Alexandre Wojcinski, Sarabjot Pabla, R J Seager, Jaya Mini Gill, Jose Carrillo, Naveed Wagle, David J. Park, Minhdan Nguyen, Judy D Truong, Yuki Takasumi, Lisa Chaiken, Shu-Ching Chang, Garni Barkhoudarian, Daniel F Kelly, and Tiffany Juarez
Kinetic Trajectories of Glucose Uptake in Single Cancer Cells Reveal a Drug-Induced Cell-State Change Within Hours of Drug Treatment., Jungwoo Kim, Rachel H Ng, JingXin Liang, Dazy Johnson, Young Shik Shin, Arion F Chatziioannou, Michael E Phelps, Wei Wei, Raphael D Levine, and James R Heath
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies., Lars Erik Kristensen, William Tillett, Peter Nash, Laura C Coates, Philip Mease, Alexis Ogdie, Paolo Gisondi, Barbara Ink, Adam R Prickett, Rajan Bajracharya, Vanessa Taieb, Nikos Lyris, Jérémy Lambert, and Jessica A Walsh
Toxin-Induced Liver Injury and Extracorporeal Treatment of Liver Failure., Angela H Lam and Joshua D King
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study., Bob T Li, Funda Meric-Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian Churchill Anderson, Giuseppe Curigliano, Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura, and DESTINY-PanTumor01 study group
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial., Kenneth W Mahaffey, Katherine Tuttle, Mustafa Arici, Florian M M Baeres, George Bakris, David M Charytan, David Z I Cherney, Gil Chernin, Ricardo Correa-Rotter, Janusz Gumprecht, Thomas Idorn, Giuseppe Pugliese, Ida Kirstine Bull Rasmussen, Søren Rasmussen, Peter Rossing, Ekaterina Sokareva, Johannes F E Mann, Vlado Perkovic, and Richard Pratley
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial., Johannes F E Mann, Peter Rossing, George Bakris, Nicolas Belmar, Heidrun Bosch-Traberg, Robert Busch, David M Charytan, Samy Hadjadj, Pieter Gillard, José Luis Górriz, Thomas Idorn, Linong Ji, Kenneth W Mahaffey, Vlado Perkovic, Søren Rasmussen, Roland E Schmieder, Richard E Pratley, and Katherine Tuttle
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients., Yang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, John Foley, Kyle E Smoot, Erin E Longbrake, Derrick Robertson, Jason P Mendoza, James B Lewin, Nicholas Everage, Ivan Božin, Jennifer Lyons, Oksana Mokliatchouk, Eris Bame, and Fabrizio Giuliani
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial., Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, Parminder K Judge, Doreen Zhu, Emily Sammons, David Zi Cherney, Alfred K Cheung, Aldo P Maggioni, Masaomi Nangaku, Xavier Rossello, Katherine Tuttle, Katsuhito Ihara, Tomoko Iwata, Christoph Wanner, Jonathan Emberson, David Preiss, Martin J Landray, Colin Baigent FMedSci, Richard Haynes, and William G Herrington
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk., Rozalina G McCoy, Jeph Herrin, Kavya Sindhu Swarna, Yihong Deng, David M Kent, Joseph S Ross, Guillermo E Umpierrez, Rodolfo J Galindo, William H Crown, Bijan J Borah, Victor M Montori, Juan P Brito, Joshua J Neumiller, Mindy M Mickelson, and Eric C Polley
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies., Iain B McInnes, Philip Mease, Yoshiya Tanaka, Laure Gossec, M Elaine Husni, Lars Erik Kristensen, Richard B Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, and Alice B Gottlieb
Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis., Philip Mease, Dafna D Gladman, Joseph F Merola, Peter Nash, Stacy Grieve, Victor Laliman-Khara, Damon Willems, Vanessa Taieb, Adam R Prickett, and Laura C Coates
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies., Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, and Laura C Coates
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, and Iain B McInnes
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Philip J Mease, Richard B Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Iain B McInnes
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, and Joseph F Merola
Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer., Alberto Mendoza-Valderrey, Jane Choe, Daria Kessler, Gianna Jimenez, Xinmin Li, Steven E Kolker, Warren M Allen, Jennifer M Linehan, Przemyslaw W Twardowski, and Maria Ascierto
The intersection of frailty and metabolism., Manish Mishra, Judy Wu, Alice E Kane, and Susan E Howlett
Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study., Yuichiro Mori, Toshiaki Komura, Motohiko Adomi, Ryuichiro Yagi, Shingo Fukuma, Naoki Kondo, Motoko Yanagita, O Kenrik Duru, Katherine Tuttle, and Kosuke Inoue
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies., Victoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, Marina Magrey, Helena Marzo-Ortega, Philip Mease, Jessica A Walsh, Maxime Dougados, Christine de la Loge, Carmen Fleurinck, Ute Massow, Thomas Vaux, Vanessa Taieb, and Atul Deodhar
Insulin Icodec., Matthew Nelson
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis., Brendon L Neuen, Robert A Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil Badve, Katherine Tuttle, Richard Pratley, Hertzel C Gerstein, Vlado Perkovic, and Hiddo J L Heerspink
Permanent Pacing Reduces Blood Pressure in Older Patients with Drug-resistant Hypertension: A New Pacing Paradigm?, Bich Lien Nguyen, Michael H Burnam, Francesco Accardo, Angela Angione, Roberto Scacciavillani, Carly Pierson, and Eli S Gang
Real world experience with sodium phenylbutyrate-taurursodiol for ALS: Lessons learned from a failed drug., Nicholas T Olney and Michael D Weiss
Med rec double check: Inpatient psychiatry medication errors identified on admission using Medicaid Web portals and electronic pharmaceutical claims data., Su Su E Oo and Ian R McGrane
7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC, L Paz-Ares, Rachel E Sanborn, and See full list of authors in comments
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply., Vlado Perkovic, Katherine Tuttle, and Richard Pratley
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial., Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, Michael H Rivner, Jonathan Katz, Angela Genge, Nicholas T Olney, Dale Lange, Daragh Heitzman, Cynthia Bodkin, Omar Jawdat, Namita A Goyal, Jeffrey D Bornstein, Carmen Mak, Stanley H Appel, and Sabrina Paganoni
IV vs PO: The Acetaminophen Showdown at Swedish, Diem Pham, Adam Corson, and Renee Rassilyer-Bomers
Enoxaparin Failure in Patient With Cerebral Venous Sinus Thrombosis and Prothrombin G20210A Mutation: Case Report., Adithya Polavarapu, Anita Bhushan, Walter Duarte-Celada, Thomas Windisch, and Bharat Bhushan
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial., Richard E Pratley, Katherine Tuttle, Peter Rossing, Søren Rasmussen, Vlado Perkovic, Olav Wendelboe Nielsen, Johannes F E Mann, Richard J MacIsaac, Mikhail N Kosiborod, Zdravko Kamenov, Thomas Idorn, Marco Bo Hansen, Samy Hadjadj, George Bakris, Florian M M Baeres, and Kenneth W Mahaffey
Polyurethane: An Old Material for a New Generation of Antibiotic Spacer Implants., James W Pritchett
Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia., Guangrong Qin, Jin Dai, Sylvia Chien, Timothy J Martins, Brenda Loera, Quy H Nguyen, Melanie L Oakes, Bahar Tercan, Boris Aguilar, Lauren Hagen, Jeannine McCune, Richard Gelinas, Raymond J Monnat, Ilya Shmulevich, and Pamela S Becker
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis., Proton Rahman, Iain B McInnes, Atul Deodhar, Georg Schett, Philip Mease, May Shawi, Daniel J Cua, Jonathan P Sherlock, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Christopher T Ritchlin, and Dennis McGonagle
Semaglutide vs Tirzepatide Dosages for Weight Loss-Reply., Patricia J Rodriguez, Tyler J Gluckman, and Nicholas Stucky
Key considerations in navigating ticagrelor's reported effect on heparin-induced thrombocytopenia functional assays in a landscape of limited data., Genene Salman, Herman J Johannesmeyer, and Martin J Breen
Evaluation of Aluminum Exposure in Neonates Receiving Parenteral Nutrition, Emma Sedarski
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial., Meghan E Sise, Jose Ramon Santos, Jason D Goldman, Katherine Tuttle, J Pedro Teixeira, Allan F Seibert, Yiannis Koullias, Joe Llewellyn, Sean Regan, Yang Zhao, Hailin Huang, Robert H Hyland, Anu Osinusi, Helen Winter, Rita Humeniuk, Henry N Hulter, Robert L Gottlieb, Dahlene N Fusco, Rita Birne, Fernando F Stancampiano, Claudia R Libertin, Catherine B Small, Markus Plate, Mark J McPhail, REDPINE Investigators, and Katherine Tuttle
Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT)., Kyle E Smoot, Horia Marginean, Tiffany Gervasi-Follmar, and Chiayi Chen
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL., Jacob D Soumerai, Jacqueline Claudia Barrientos, Inhye E Ahn, Catherine C Coombs, Douglas E Gladstone, Marc S Hoffmann, Adam S Kittai, Ryan W Jacobs, Andrew Lipsky, Krish Patel, Joanna M Rhodes, Alan P Skarbnik, Meghan C Thompson, Daniel A Ermann, Patrick K Reville, Harsh R Shah, Jennifer R Brown, and Deborah M Stephens
Chronic use of Antihypertensive Medications and Peak Exercise Blood Pressure in Adult Men and Women from the BALL ST Cohort., Emily Spencer, Mary Imboden, James E Peterman, Mitchell H Whaley, Leonard A Kaminsky, Bradley S Fleenor, and Matthew P Harber
Adherence to SB5195 Naloxone Distribution Requirements at Discharge from the Emergency Department, E Stewart, J Delfeld, J McKay, J Corhei, and Kailyn Elliot
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial., Vibeke Strand, Laure Gossec, Laura C Coates, Alexis Ogdie, Jiyoon Choi, Brandon Becker, Joe Zhuo, Thomas Lehman, Miroslawa Nowak, Ayanbola Elegbe, Philip Mease, and Atul Deodhar
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials., Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B Gottlieb, Philip Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, and Victor Dong
Safety of Ketamine Use for Rapid Control of Agitation in the Emergency Department, Rosa Hong Trieu
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial., Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J L Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, Peter Rossing, and ASi in CKD group
Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock., Saraschandra Vallabhajosyula, Anthony J Faugno, Borui Li, Kevin John, Qiuyue Kong, Shashank S Sinha, Jaime Hernandez-Montfort, Manreet K Kanwar, Jacob Abraham, Vanessa Blumer, Maryjane Farr, Justin Fried, Arthur R Garan, Shelley Hall, Gavin W Hickey, Rachna Kataria, J U Kim, Song Li, Claudius Mahr, Sandeep Nathan, Mohit Pahuja, Paavni Sangal, Andrew Schwartzman, VAN-Khue Ton, Oleg A Vishnevsky, Esther Vorovich, Karol D Walec, Peter Zazzali, Elric Zweck, Daniel Burkhoff, and Navin K Kapur
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice., Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, and Henry G Kaplan
Evaluation of Piperacillin-Tazobactam Dosing and Clinical Outcomes in Obese Patients, Maria C. Vazquez, Shalyn Cox, and Larry J Pineda
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202., A Vogel, V Sahai, A Hollebecque, G M Vaccaro, D Melisi, R M Al Rajabi, A S Paulson, M J Borad, D Gallinson, A G Murphy, D-Y Oh, E Dotan, D V Catenacci, E Van Cutsem, C F Lihou, H Zhen, M L Veronese, and G K Abou-Alfa
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment., Xiaoqiang Wang, Shoubao Ma, Przemyslaw W Twardowski, Clayton Lau, Yin S Chan, Kelly Wong, Sai Xiao, Jinhui Wang, Xiwei Wu, Paul Frankel, Timothy G Wilson, Timothy W Synold, Cary Presant, Tanya Dorff, Jianhua Yu, David Sadava, and Shiuan Chen
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison., Richard B Warren, Iain B McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, and Philip Mease
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With, Francis P Worden, Evan Pisick, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Maged F Khalil, Daniel R Carrizosa, Jessica R Bauman, Rom Leidner, Herbert L Duvivier, Siqing Fu, Min Park, Kathleen J Yost, Carmen J Calfa, Alissa S Marr, Ani S Balmanoukian, Deepti Behl, Timothy L Cannon, Lisle Nabell, Steven Francis Powell, Ramya Thota, Dominique C Hinshaw, Abigail Gregory, Gina N Grantham, Susan Halabi, and Richard L Schilsky
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation., Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor, Jonathan Eliezer Cohen, Daniel W Bowles, Shirish M Gadgeel, Catalin Mihalcioiu, Kyriakos P Papadopoulos, Eli L Diamond, Keren B Sturtz, Gang Feng, Stefanie K Drescher, Micaela B Reddy, Bhaswati Sengupta, Arnab K Maity, Suzy A Brown, Anurag Singh, Eric N Brown, Brian R Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R Kahn, Sunyana Gadal, Neal Rosen, John J Gaudino, Patrice A Lee, Dylan P Hartley, and S Michael Rothenberg
Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial., Andres J Yarur, Michael Chiorean, Julián Panés, Vipul Jairath, Jinkun Zhang, Christopher J Rabbat, William J Sandborn, Séverine Vermeire, and Laurent Peyrin-Biroulet
Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program., Andres J Yarur, Michael V Chiorean, Jessica R Allegretti, Raymond K Cross, Christina Ha, Martina Goetsch, Aoibhinn McDonnell, Alexis B Dalam, Joseph Wu, David A Blanco, Arcangelo M Abbatemarco, and Julian Panés
Detection and Quantification of Drug-Protein Adducts in Human Liver., Alex Zelter, Michael Riffle, David D Shteynberg, Guo Zhong, Ellen B Riddle, Michael R Hoopmann, Daniel Jaschob, Robert L Moritz, Trisha N Davis, Michael J MacCoss, and Nina Isoherranen
From Hormones to Pancreatitis: A Case of Estrogen-Induced Hypertriglyceridemia, Kyaw Zin (Kennis) Htet, MD; Michael Lefor, MD; and Brinton Clark, MD
A new era in the science and care of kidney diseases., Carmine Zoccali, Francesca Mallamaci, Liz Lightstone, Vivek Jha, Carol Pollock, Katherine Tuttle, Peter Kotanko, Andrzej Wiecek, Hans Joachim Anders, Giuseppe Remuzzi, Kamyar Kalantar-Zadeh, Adeera Levin, and Raymond Vanholder
